

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LifeTech Scientific Corporation**

**先健科技公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1302)**

### **INSIDE INFORMATION**

#### **CONVERSION OF FIRST TRANCHE CONVERTIBLE NOTES**

On 22 December 2016, the Company received a written notice from Medtronic for the exercise of the conversion rights attaching to the First Tranche Convertible Notes in the principal amount of HK\$152,000,000 at the conversion price of HK\$0.475 per Share. It is expected that 320,000,000 Conversion Shares will be issued to Medtronic on or about 29 December 2016. The Conversion Shares, when issued, will rank pari passu with all the existing Shares as at the date of issue and among themselves in all respects.

Upon the issue of the Conversion Shares and assuming that there will be no other changes in the number of issued Shares from the date of this announcement up to (and including) the date of issue of the Conversion Shares, there will be 4,320,264,000 Shares in issue.

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 15 October 2012, 28 December 2012, 6 January 2013 and 30 January 2013 and the circular (the “**Circular**”) of the Company dated 6 January 2013 in connection with, among other things, the issue of the First Tranche Convertible Notes by the Company to Medtronic in the principal amount of HK\$152,000,000.

## CONVERSION OF FIRST TRANCHE CONVERTIBLE NOTES

On 22 December 2016, the Company received a written notice from Medtronic for the exercise of the conversion rights attaching to the First Tranche Convertible Notes in the principal amount of HK\$152,000,000 at the conversion price of HK\$0.475 per Share. It is expected that 320,000,000 Conversion Shares will be issued to Medtronic on or about 29 December 2016. The Conversion Shares, when issued, will rank pari passu with all the existing Shares as at the date of issue and among themselves in all respects.

Upon the issue of the Conversion Shares and assuming that there will be no other changes in the number of issued Shares from the date of this announcement up to (and including) the date of issue of the Conversion Shares, there will be 4,320,264,000 Shares in issue.

## EFFECT ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Assuming that there will be no other changes in the number of issued Shares from the date of this announcement up to (and including) the date of issue of the Conversion Shares, the shareholding structure of the Company (i) as at the date of this announcement and (ii) immediately after the issue of the Conversion Shares is set out below:

	As at the date of this announcement		Immediately after the issue of the Conversion Shares	
	<i>Number of Shares</i>	<i>Approximate %</i>	<i>Number of Shares</i>	<i>Approximate %</i>
<b>Non-public Shareholders</b>				
Xianjian Advanced Technology Limited (Note 1)	781,914,928	19.55	781,914,928	18.10
GE Asia Pacific Investments Ltd. (Note 1)	358,852,656	8.97	358,852,656	8.31
Medtronic KL Holdings LLC (Note 2)	760,000,000	19.00	1,080,000,000	25.00
Liu Jianxiong (Note 3)	8,000,000	0.20	8,000,000	0.19
<b>Sub-total</b>	<b>1,908,767,584</b>	<b>47.72</b>	<b>2,228,767,584</b>	<b>51.60</b>
<b>Public Shareholders</b>	<b>2,091,496,416</b>	<b>52.28</b>	<b>2,091,496,416</b>	<b>48.40</b>
<b>Total</b>	<b>4,000,264,000</b>	<b>100.00</b>	<b>4,320,264,000</b>	<b>100.00</b>

*Notes:*

1. All the issued shares of Xianjian Advanced Technology Limited are owned by Mr. Xie Yuehui, the chairman, the chief executive officer and an executive director of the Company. All the issued shares of GE Asia Pacific Investments Ltd. are owned by Mr. Wu Jianhui, a former non-executive Director. Xianjian Advanced Technology Limited and GE Asia Pacific Investments Ltd. are parties acting in concert.
2. The entire issued share capital of Medtronic KL Holdings LLC is controlled as to 90.33% by Medtronic Holding Switzerland G.m.b.H., which in turn is wholly-owned by Medtronic B.V.. Medtronic B.V. is wholly-owned by Medtronic International Technology, Inc., which in turn is wholly-owned by Medtronic, Inc.. Medtronic, Inc. is wholly owned by Medtronic Holding, Inc., which in turn is wholly owned by Medtronic Group Holding, Inc.. Medtronic Group Holding, Inc. is wholly owned by Medtronic plc.
3. Mr. Liu Jianxiong is an executive Director.

## **DEFINITIONS**

Capitalised terms used in this announcement shall have the same meaning as defined in the Circular, unless the context otherwise requires or they are defined as follows:

“Company”	LifeTech Scientific Corporation, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange after being transferred from the Growth Enterprise Market of the Stock Exchange on 6 November 2013 (Stock Code: 1302)
“Share(s)”	ordinary share(s) of US\$0.00000125 each in the share capital of the Company

By Order of the Board  
**LifeTech Scientific Corporation**  
**XIE Yuehui**  
*Executive Director, Chairman and  
Chief Executive Officer*

Hong Kong, 22 December 2016

*As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. XIAO Ying being executive Directors; Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.*